When was Avanir founded?

Avanir was founded in 1988 and raised its 1st funding round 24 years after it was founded.

Where is Avanir located?

Avanir is headquartered in Aliso Viejo, United States.

How many employees does Avanir have?

As of Sep 30, 2026, the latest employee count at Avanir is 127.

Is Avanir a funded company?

Avanir is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Jun 26, 2012.

When was the latest funding round of Avanir?

Avanir's latest funding was a $***** Conventional Debt round on Jun 26, 2012, with participation from 2 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.6B in funding in 2026 to date.

Where does Avanir rank among its competitors?

Avanir ranks 1035th amongst 2945 active competitors, of which 976 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was MapLight, which secured $150M in Aug, 2026.

Who are the top competitors of Avanir?

Avanir's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, MapLight secured the most recent funding round in August, 2026.

Avanir - 2026 Company Profile, Funding & Competitors

Q: Is Avanir an acquired company?

Avanir got acquired by Otsuka on Dec 02, 2014.

Avanir is an acquired company based in Aliso Viejo (United States), founded in 1988. It operates as an Acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.. Avanir has raised an undisclosed amount in funding. The company has 2945 active competitors, including 976 funded and 720 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Avanir Pharmaceuticals, is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. It markets Nuedecta, (dextromethorphan hydrobromide and quinidine sulfate) 20/10 mg capsules, which is FDA-approved for the treatment of pseudobulbar affect (PBA); Onzetra Xsail (sumatriptan nasal powder), FDA-approved for the acute treatment of migraine with or without aura in adults. Its clinical stage product is AVP-786 in development to treat Alzheimer’s DiseaseDepression Schizophrenia

Key Metrics

Founded Year

1988

Location

Aliso Viejo, United States

Stage

Acquired

Latest Funding Round

Conventional Debt, Jun 26, 2012, $*****

Investors

Foresite Capital & 5 more

Ranked

1035^th among 2945 active competitors

Employee Count

127 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 612 more

Exit Details

Acquired by Otsuka (Dec 02, 2014)

View Avanir's full profile

Avanir is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Avanir Pharmaceuticals, Inc. CIN: 33-0314804 , United States, Active	Dec 31, 1987	-	-	-

Avanir got acquired by Otsuka on Dec 02, 2014 at an acquisition amount of $*****.

Click here to take a look at Avanir's acquisition in detail

Avanir has raised funding over 1 round. Its latest funding round was a Conventional Debt round on Jun 26, 2012 for $*****. 2 investors participated in its latest round. Avanir has 6 institutional investors.

Here is the list of recent funding rounds of Avanir:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 26, 2012	6818654	Conventional Debt	9922039	8887178	1858007	9709850

Access funding benchmarks and valuations. Sign up today!

View details of Avanir's funding rounds and investors

Avanir's employee count trend

Avanir has 127 employees as of Sep 26. Here is Avanir's employee count trend over the years:

Uncover Avanir's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avanir include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Avanir, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 29 others	73/100
4th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
5th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	MapLight 2018, Redwood City (United States), Public	Developer of therapeutic for central nervous system disorders	$698M	Goldman Sachs, Cowen & 11 others	70/100
10th	Philogen 1996, Sovicille (Italy), Public	Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders	$69.7M	The Equity Club, Novacapital & 3 others	70/100
1035th	Avanir 1988, Aliso Viejo (United States), Acquired	Acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.	-	Foresite Capital, ProQuest Investments & 4 others	38/100